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Abstract
Objective To review the evidence on the cost-effectiveness
of heart valve implantations generated by decision analytic
models and to assess their methodological quality.
Methods A systematic review was performed including
model-based cost-effectiveness analyses of heart valve
implantations. Study and model characteristics and cost-
effectiveness results were extracted and the methodological
quality was assessed using the Philips checklist.
Results Fourteen decision-analytic models regarding the
cost-effectiveness of heart valve implantations were iden-
tified. In most studies transcatheter aortic valve implanta-
tion (TAVI) was cost-effective compared to standard
treatment (ST) in inoperable or high-risk operable patients
(ICER range 18,421–120,779 €) and in all studies surgical
aortic valve replacement (SAVR) was cost-effective com-
pared to ST in operable patients (ICER range
14,108–40,944 €), but the results were not consistent on
the cost-effectiveness of TAVI versus SAVR in high-risk
operable patients (ICER range: dominant to dominated by
SAVR). Mechanical mitral valve replacement (MVR) had
the lowest costs per success compared to mitral valve
repair and biological MVR. The methodological quality of
the studies was moderate to good.
Conclusion This review showed that improvements can be
made in the description and justification of methods and
data sources, sensitivity analysis on extrapolation of
results, subgroup analyses, consideration of methodologi-
cal and structural uncertainty, and consistency (i.e. valid-
ity) of the models. There are several opportunities for
future decision-analytic models of the cost-effectiveness of
heart valve implantations: considering heart valve
implantations in other valve positions besides the aortic
valve, using a societal perspective, and developing patient-
simulation models to investigate the impact of patient
characteristics on outcomes.
Keywords Systematic review  Decision-analytic model 
Economic evaluation  Heart valve implantations
JEL Classification I190
Introduction
The first cost-effectiveness analysis on heart valve
implantations was published by Wu et al. [1]. They esti-
mated the cost-effectiveness of surgical aortic valve
replacement (SAVR: replace native heart valve with a
prosthetic heart valve during open heart surgery) compared
to standard treatment (ST: often medical management) and
found that SAVR was cost-effective [1]. The number of
cost-effectiveness analyses on heart valve implantations
increased after the introduction of an alternative treatment
for severe aortic valve stenosis: transcatheter aortic valve
implantation (TAVI: prosthetic heart valve implanted with
a catheter, no open heart surgery required).
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In 2010, the first model-based cost-effectiveness analy-
sis of TAVI compared to ST and SAVR concluded that
TAVI had high potential to be cost-effective for inoperable
patients, but the cost-effectiveness of patients with lower
operable risk was uncertain [2]. Healthcare decision mak-
ers required further evidence on the clinical effectiveness
of TAVI to make a reimbursement decision. The Placement
of Aortic Transcatheter Valves (PARTNER) trial was the
first randomized controlled trial for TAVI [3, 4]. Based on
the PARTNER trial results, in 2012 the National Institute
for Health and Care Excellence approved reimbursement of
TAVI for inoperable patients in the UK but reimbursement
for operable patients is still under review [5].
Since then almost every cost-effectiveness analysis
investigating TAVI based their clinical effectiveness
parameters on the PARTNER trial. There are two trial-
based cost-effectiveness analyses [6, 7]; the other cost-ef-
fectiveness analyses are based on decision-analytic models.
Decision-analytic models represent an explicit way to
synthesize evidence on the outcomes and costs of alterna-
tive interventions [8].
We are currently developing a decision-analytic model
to estimate the cost-effectiveness of current and future
heart valve interventions (e.g. tissue-engineered heart
valves) [9]. In this light, careful review of existing deci-
sion-analytic models addressing related problems is a
prerequisite [10].
The goal of this study is to investigate the opportunities
for new decision-analytic models in the field of heart valve
interventions and to learn from the methodological choices
made by previous model developers. Therefore, and in
contrast with previous reviews [11–13], we focus on
decision-analytic models and exclude cost-effectiveness
analyses alongside clinical trials. Furthermore, we are not
only interested in decision-analytic models investigating
the cost-effectiveness of SAVR and TAVI but we also
include decision-analytic models for other heart valve
implantations.
Methods
Search strategy and selection criteria
This systematic review was conducted according to
PRISMA guidelines [14]. On May 28, 2015 several data-
bases were searched (Electronic supplementary material:
Appendix 1). Two reviewers (SH & JT or SH & MR)
independently determined whether the publications met the
inclusion criteria. In case of disagreement, an agreement
was negotiated. Publications were included when they
reported model-based economic evaluations considering
costs and health outcomes of heart valve implantations.
Papers solely describing regression models, cost-analyses,
non-English publications, conference abstracts, editorials
and letters to the editor were excluded. References of
selected papers and previous systematic reviews [11–13]
were crosschecked for other relevant studies.
Data extraction
Study and model characteristics and cost-effectiveness
results were extracted. Costs were inflated to 2015 and
converted to euros(€) using purchaser power parities and
exchange rates [15, 16].
Cost-effectiveness thresholds
Reported cost per quality adjusted life years (QALY) ratios
were compared to thresholds used in individual studies and
thresholds based on the WHO-CHOICE approach where
interventions are highly cost-effective when they have
incremental cost-effectiveness ratios (ICER) below the gross
domestic product (GDP)/capita, cost-effective if the ICER is
1–3 times the GDP/capita, and not cost-effective when the
ICER is more than 3 times the GDP/capita [17, 18].
Methodological quality assessment
The ‘Drummond checklist’ [19] and ‘Evers checklist’ [20]
are often used to appraise methodological quality of eco-
nomic evaluations conducted alongside clinical trials.
Although these checklist are relevant, they are not sufficient
to appraise the quality ofmodel based economic evaluations.
Therefore, we chose to use the Philips checklist to critically
appraise the methodological quality of studies [8]. This
checklist is divided into three sections: structure, data and
consistency.Within each section criteria can be fulfilled, not
fulfilled or not applicable. The checklist was assessed for
every study by two reviewers (SH& JT or SH&MR). In case
of disagreement, an agreement was negotiated. This
assessment had a qualitative nature and studies were not
excluded because of low quality scores.
Results
The literature search resulted in 1019 studies, of which 14
studies were included (Fig. 1) [2, 21–33].
Study and model characteristics
Tables 1 and 2 provide an overview of study and model
characteristics. Table 1 is structured by valve position and
interventions and comparators; TAVI versus ST (often
inoperable patients), TAVI versus SAVR (often high
S. A. Huygens et al.
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operable risk patients), SAVR versus ST (operable
patients) and mitral valve repair versus mitral valve
replacement (operable patients).
Cost-effectiveness outcomes
Table 3 shows the cost-effectiveness outcomes structured
by valve position and interventions and comparators.
TAVI versus ST (often inoperable patients)
The costs of TAVI compared to ST were higher, but
QALYs gained were also higher. According to thresholds
used in individual studies, TAVI is cost-effective compared
to ST in eight studies [2, 22, 25–27, 30, 31, 33] and not
cost-effective in four studies [23, 28, 29, 32]. When
applying the WHO-CHOICE approach, TAVI is cost-ef-
fective compared to ST in all studies and even highly cost-
effective (ICER\GDP/capita) in seven studies
[2, 22, 25–27, 30, 33].
TAVI versus SAVR (often high-risk operable patients)
TAVI was dominated by SAVR (i.e. higher costs, lower
QALY gain) in three studies [23, 26, 30], high ICERs were
reported in three studies [2, 25, 29], and TAVI was
dominant in one study [24] (i.e. lower costs, higher QALY
gain). According to thresholds used in individual studies,
TAVI was not cost-effective in two of three studies where
TAVI was not dominant or dominated by SAVR [2, 29].
Using the WHO-CHOICE approach, TAVI was not cost-
effective compared to SAVR in Neyt et al. [29], and TAVI
was cost-effective in the SHTG report [2] and in Gada et al.
[25].
SAVR versus ST (operable patients)
SAVR gains more QALYs at higher costs than ST.
According to thresholds used in individual studies and the
WHO-CHOICE approach SAVR is (highly) cost-effective
compared to ST in all studies.
Mitral valve repair versus mitral valve replacement
(operable patients)
One study evaluated heart valve implantations in the mitral
valve position [21]. They found that mechanical mitral
valve replacement has the lowest costs per success (when
using a 20-year time horizon). To compare these results
with heart valve implantations in other valve positions and
to assess whether it falls below the cost-effectiveness
threshold, the effects should be expressed in QALYs.
Fig. 1 Study selection
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Table 1 Study characteristics
Author and year
of publication
Target population Clinical
effectiveness data
sourcec
Mean
patient
age
Logistic
EuroSCORE
NYHA
class
III/IV
(%)
Intervention
of interest
Comparator
I C I C I C
TAVI versus ST (often inoperable patients)
SHTG 2010 [2] Medium risk AS patients: patients for
whom there is not currently a clear
choice of treatment, as such the choice
considered in the analysis is between
SAVR, TAVI and MM
REVIVE 70 70 NR NR NR NR TAVIb MM
High-risk AS patients: patients who are
ineligible for conventional surgery so
traditionally get medical management,
as such the choice is between TAVI
and MM
80 80
Gada et al. 2012
[25]
High-risk severe AS operable patients:
patients with a logistic
EuroSCORE[15% and/or STS
score[10%
8 registries 82 77 26 21 87 90 TAVI (TF) MMa
Gada et al. 2012
[26]
20 registries 82 81 29 31 77 87 TAVI (TA)
Neyt et al. 2012
[29]
Inoperable SSAS patients: patients with
coexisting conditions associated with a
predicted probability of C50% of
death by 30 days after surgery or a
serious irreversible condition. At least
two surgeon investigators had to agree
that the patient was not a
suitable candidate for surgery
PARTNER-B 83 83 26 30 92 94 TAVI (TF) ST (including
MM and/or
BAV)Watt et al. 2012
[33]
Doble et al. 2013
[23]
Hancock-Howard
et al. 2013 [27]
Murphy et al. 2013
[28]
Queiroga et al.
2013 [31]
Simons et al. 2013
[32]
Orlando et al. 2013
[30]
Patients unsuitable for SAVR: patients
with coexisting conditions associated
with a predicted probability of C50%
of death by 30 days after surgery or a
serious irreversible condition. At least
two surgeon investigators had to agree
that the patient was not a
suitable candidate for surgery
PARTNER-B 83 83 26 30 92 94 TAVIb MM
Brecker et al. 2014
[22]
Inoperable and high-risk SSAS patients:
Patients considered inoperable or at
higher risk for SAVR and
anatomically acceptable candidates for
elective treatment with the CoreValve
System
ADVANCE (all
TAVI patients)
PARTNER-B (ST
patients)
81 83 19 30 80 94 TAVI (TF,
direct aortic,
or
subclavian)
ST (including
MM and/or
BAV)
ADVANCE (TAVI
patients
with[20%
logistic
EuroSCORE)
PARTNER-B (ST
patients)
83 83 32 30 85 94
TAVI versus SAVR (often high-risk operable patients)
SHTG 2010 [2] Low-risk AS patients: patients who are
assumed to be eligible for SAVR but
for whom TAVI could be an
alternative
REVIVE 60 60 NR NR NR NR TAVIb SAVR
Medium risk AS patients: patients for
whom there is not currently a clear
choice of treatment, as such the choice
considered in the analysis is between
SAVR, TAVI and MM
70 70
S. A. Huygens et al.
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Table 1 continued
Author and year of
publication
Target population Clinical
effectiveness data
sourcec
Mean
patient
age
Logistic
EuroSCORE
NYHA
class III/
IV (%)
Intervention
of interest
Comparator
I C I C I C
Gada et al. 2012
[25]
High-risk severe AS operable patients:
patients with a logistic
EuroSCORE[15% and/or STS
score[10%
8 registries 82 77 26 21 86 90 TAVI (TF) SAVR
Gada et al. 2012
[26]
20 registries 82 81 29 31 77 87 TAVI (TA)
Neyt et al. 2012
[29]
High-risk operable SSAS patients:
patients with a predicted risk of
operative mortality rate of C15% or a
Society of Thoracic Surgery risk score
of C10%
PARTNER-A 84 85 29 29 94 94 TAVI
(TF ? TA)
SAVR
Doble et al. 2013
[23]
Fairbairn et al.
2013 [24]
Orlando et al. 2013
[30]
Patients suitable for SAVR:
TAVI and MM patients
Inoperable SSAS patients from the
PARTNER-B trial: patients with
coexisting conditions associated with a
predicted probability of C50% of
death by 30 days after surgery or a
serious irreversible condition. At least
two surgeon investigators had to agree
that the patient was not a
suitable candidate for surgery
SAVR patients
Patients undergoing isolated SAVR
PARTNER-B (for
TAVI and MM)
and two cohort
studies [50, 51]
(for SAVR)
83 NR 29 10–20 92 NR TAVI
(TF ? TA)
SAVR (90%)
MM (10%)
SAVR versus ST (operable patients)
SHTG 2010 [2] Medium risk AS patients: patients for
whom there is not currently a clear
choice of treatment, as such the choice
considered in the analysis is between
SAVR, TAVI and MM
REVIVE 70 70 NR NR NR NR SAVR MM
Gada et al. 2012
[25]
High-risk severe AS operable patients:
patients with a logistic
EuroSCORE[15% and/or STS
score[10%
8 registries 82 77 26 21 86 90 SAVR MMa
Gada et al. 2012
[26]
20 registries 82 81 29 31 77 87
Mitral valve repair versus replacement (operable patients)
Beresniak et al.
2013 [21]
Patients with mitral valve disease
undergoing surgical mitral valve repair
or replacement
Cohort study of the
Georges
Pompidou
European
Hospital
NR NR NR NR NR NR Surgical
mitral valve
repair
Surgical
mitral valve
replacement
I intervention of interest, C comparator, NR not reported, SSAS severe symptomatic aortic stenosis, defined as an aortic valve area 0.8 cm2 with
either a mean valve gradient[ 40 mm Hg or a peak jet velocity[ 4.0 m/s. AS aortic stenosis, SAVR surgical aortic valve replacement, TAVI
transcatheter aortic valve replacement, TF transfemoral, TA transapical, MM medical management, ST standard therapy, including MM and/or
balloon aortic valvuloplasty (BAV). NYHA class New York Heart Association class. PARTNER-A comparing TAVI with SAVR in high-risk
operable patients [3]. PARTNER-B comparing TAVI with MM/ST in inoperable patients [4]. REVIVE the Registry of Endovascular Implantation
of Valves in Europe trial started in 2003 in a single centre in France with the aim of studying the feasibility and safety of TAVI in inoperable
patients [52]. ADVANCE multicentre, non-randomized study that included 44 centres in 12 countries evaluating the outcomes of a self-expanding
transcatheter aortic valve system in patients considered inoperable or at a higher surgical risk [53]
a Medical management comprised antithrombotic therapy for treatment of concomitant coronary artery disease or atrial fibrillation, antihy-
pertensive drugs in case of arterial hypertension, statins for treatment of hypercholesterolemia, and diuretics for management of heart failure
symptoms, rarely complemented by digoxin [54]
b Implantation route not defined
c The sources of other data types (mortality, resource use, costs and utilities) can be found in Table A2.2 in the Electronic supplementary
material
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Table 2 Model characteristics
Author and
year of
publication
Model type Health states Time horizon Cycle
length
Discount
rate
Study
perspective
Country
SHTG
2010 [2]
Decision
tree;
Markov
model
Short-term: dead, alive, major (assumed to result in
failure of the valve implantation with the patient
left in a state no better than their original
manifestation of AS), minor (assumed to resolve
with appropriate medical care), or no procedure
related event, convert to SAVR, convert to MM,
AS/failed valve replacement, and functioning
valve replacement
Long-term: AS/failed valve replacement, procedure
related event, functioning valve replacement,
death
1 month; until
the majority of
patients have
died
N/A;
1 year
C: 3.5%
E: 3.5%
Healthcare UK
Gada et al.
2012 [25]
Markov
model
Medical management, screened for TAVI, SAVR
and peri-procedural risks, TAVI and peri-
procedural risks, post-SAVR or TAVI
complication (including endocarditis, hemorrhage,
valve thrombosis, and non-cerebral), heart failure,
stroke, dead
Lifetime 1 year C: 5%
E: –
Healthcare
payer
US
Gada et al.
2012 [26]
Neyt et al.
2012 [29]
Markov
model
Mortality, hospitalization, other events (repeat
hospitalization, minor/major stroke and TIA, and
cardiac re-interventions), and no event
Lifetime/
1 yeara
1 month C: 3%
E: 1.5%
Healthcare Belgium
Watt et al.
2012 [33]
Two
interlinked
Markov
models
Short-term: ICU non-ICU, home care, post-hospital
rehabilitation (community and managed) and
death
Long-term: home care, reoperation and death
1 month;
10 years
1 day;
1 month
C: 3.5%
E: 3.5%
Healthcare UK
Beresniak
et al.
2013 [21]
Decision tree Sequential treatment switches allowed at each
5-year interval in case of failure of the former
treatment option
10/20 years N/A C: –
E: –
Healthcare France
Doble et al.
2013 [23]
Decision
tree;
Markov
model
Short-term: alive without complications, other acute
complications (endocarditis, major vascular
complications, paravalvular leaks, PI, major
bleeding, AF), stroke (temporary or permanent
disability), MI, AKI (no, temporary, and
permanent dialysis), reoperation, conversion to
SAVR, cumulative death
Long-term: alive without complications, stroke first
year, stroke subsequent years, MI first year, MI
subsequent years, post-AKI, alive and death after
complications, and death
1 month;
20 years
N/A;
1 year
C: 5%
E: –
Healthcare Canada
Fairbairn
et al.
2013 [24]
Decision
tree;
Markov
model
Short-term: after TAVI/SAVR transition to NYHA
class I-IV or dead
Long-term: transitions from NYHA class I-IV to
dead
2 years;
10 years
N/A;
1 year
C: 3.5%
E: 3.5%
Healthcare UK
Hancock-
Howard
et al.
2013 [27]
Decision tree After treatment: alive or dead. When alive: early or
no early complication. After both these health
states: late complication (major stroke with full
recovery, major stroke with ongoing care and no
stroke) or no late complication. Complications in
no stroke: valve thromboembolism, PI,
endocarditis, reoperation, MI, renal failure, BAV,
hospital readmission, SAVR. In addition to these
complications, other complications were only
considered early: major access site/vascular
complication, major paravalvular leak, and
arrhythmia/atrium fibrillation
3 years N/A C: 5%
E: 5%
Healthcare Canada
Murphy
et al.
2013
[28]b
Decision
tree;
Markov
model
Short-term: dead, alive, major (e.g. valve
thromboembolism or MI: long-term effect), minor
(e.g. PI or vascular events: short-term effect), or
no procedure related event, convert to SAVR,
convert to MM, AS/failed valve replacement, and
functioning valve replacement
Long-term: AS/failed valve replacement, procedure
related event, functioning valve replacement, and
death
1 month;
Lifetime
N/A;
1 year
C: –
E: –
Healthcare UK
S. A. Huygens et al.
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Methodological quality assessment
The assessment of methodological quality of studies using
the Philips checklist is reported in Table A2.1 in the
Electronic supplementary material. The total score repre-
sents the percentage of criteria that were fulfilled, corrected
for criteria that were not applicable, and ranged from 49 to
87%. The lowest percentage was found in the study on
mitral valve interventions [21].
Discussion
Cost-effectiveness outcomes
Even though most studies compared the same heart valve
implantations, cost-effectiveness results varied substan-
tially between studies. Based on thresholds from individual
studies or using the WHO-CHOICE approach, TAVI was
cost-effective compared to ST in inoperable or high-risk
operable patients in most studies and in all studies SAVR
was cost-effective compared to ST in operable patients.
The results were not consistent on the cost-effectiveness of
TAVI versus SAVR in high-risk operable patients, ranging
from TAVI being dominant to being dominated by SAVR.
However, the cost-effectiveness thresholds were relatively
high. The thresholds used in individual studies ranged from
£20,000/QALY to CDN$100,000/QALY and thresholds
based on the WHO-CHOICE approach ranged from
123,264 €/QALY for France to 168,198 €/QALY for the
US. When we apply the threshold of the UK
(£30,000 & €43,000/QALY), TAVI is cost-effective
compared to ST in seven instead of eight (according to
thresholds used in individual studies) or all (according to
WHO-CHOICE approach) studies. Just as with the indi-
vidual studies’ and WHO approach thresholds, SAVR is
cost-effective compared to ST in all three studies. Using
the UK threshold does not influence our conclusion on the
cost-effectiveness of TAVI versus SAVR; it remains not
cost-effective in all but one study.
Our results did not reflect a clear trend in the cost-ef-
fectiveness of heart valve implantations over time; proba-
bly due to the short time frame in which the studies were
performed ([80% in 2012–2013).
Table 2 continued
Author and
year of
publication
Model type Health states Time horizon Cycle
length
Discount
rate
Study
perspective
Country
Orlando
et al.
2013 [30]
Decision tree Suitable for surgery followed by SAVR, TAVI
(when available) and MM. Not suitable for
surgery followed by TAVI (when available) and
MM. After treatment: hospital-free survival and
other survival (surviving patients who had
undergone C1 episode of hospitalization after
initial treatment)
1 month;
25 years
N/A C: 3.5%
E: 3.5%
Healthcare UK
Queiroga
et al.
2013 [31]
Markov
model
Survival and death 5 years 3 months C: 5%
E: 5%
Healthcare Brazil
Simons
et al.
2013 [32]
Markov
model
Health states based on combination symptom status
(NYHA class I/II or III/IV) and major
complications (stroke, vascular complication,
bleed)
Lifetime 1 month C: 3%
E: 3%
Healthcarec US
Brecker
et al.
2014
[22]d
Two
interlinked
Markov
models
Short-term: ICU, non-ICU, home care, post-hospital
rehabilitation (community and managed) and
death
Long-term: home care, reoperation and death
1 month;
5 years
1 day;
1 month
C: 3.5%
E: 3.5%
Healthcare UK
C costs, E effects, N/A not applicable, AS aortic stenosis, SAVR surgical aortic valve replacement, TAVI transcatheter valve implantation, BAV
balloon aortic valvuloplasty,MM medical management, ICU intensive care unit, PI pacemaker implantation. AF atrial fibrillation,MI myocardial
infarction, AKI acute kidney injury, TIA transient ischemic attack, NYHA New York Heart Association, Healthcare perspective includes all direct
healthcare costs regardless of who pays them, Healthcare payer perspective includes all direct healthcare costs covered by the health insurer or
the NHS (i.e. the amount of costs reimbursed to the provider)
a The time horizon is lifetime in the model comparing TAVI with ST in inoperable patients and 1 year in the model comparing TAVI versus
SAVR in high-risk operable patients
b Based on model of SHTG [2]
c Societal perspective according to authors, but costs outside of healthcare are not taken into account
d Same model as Watt et al. [33]
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Methodological quality assessment
There was no correlation between methodological quality
scores and ICERs of the included studies (Spearman’s rank
correlation coefficients: TAVI vs ST (12 studies) = 0.000,
TAVI vs SAVR (7 studies) = -0.126, SAVR vs ST:
correlation not determined because there were only three
studies in this subgroup). The methodological quality
assessment showed that the decision-analytic models were
of moderate to good quality. However, authors did not
always justify their choices and assumptions and major
improvements can be made in the description of method-
ology. The following discusses our assessment of the
methodological quality, structured according to the Philips
checklist [8].
Perspective
Most studies used a healthcare perspective (i.e. include all
direct healthcare costs) and two studies used a healthcare
payer perspective (i.e. only includes healthcare costs cov-
ered by the health insurer or the NHS) [25, 26]. Simons
et al. [32] claimed to use a societal perspective while only
healthcare costs were included. Contrary to our expecta-
tions, studies performed from a healthcare payer perspec-
tive did not report significantly lower costs. However, it is
possible that the studies performed from a healthcare payer
perspective underestimated the costs of TAVI because they
both assume that payers would provide the same reim-
bursement for the TAVI and SAVR procedure and subse-
quent hospitalisation [25, 26].
The ICERs are generally the lowest in the UK and the
highest in the US. Comparisons of studies within the US
showed that the costs of TAVI in Gada et al. [25, 26] are
considerably lower than in Simons et al. [32], probably due
to the healthcare payer perspective of Gada et al. compared
to the healthcare perspective of Simons et al., the
assumption of same procedure costs for TAVI and SAVR
in Gada et al. while TAVI is, in general, more expensive,
and/or difference in operable risks (high-risk operable
patients in Gada et al. vs inoperable patients in Simons
et al.).
Rationale for structure
Many studies combined a short- (often 1 month) and long-
term model, mostly decision trees and Markov models.
Health states were based on treatment [21], ward or site
where care was provided [22, 33], New York Heart
Association (NYHA) class [24], complications
[2, 23, 25–29], survival [31], or a combination of NYHA
class and treatment or complications [30, 32]. In our view,
two studies chose a too simplistic model structure only
including health states of survival and death [31] or NYHA
classes and death [24] without explicitly including valve-
related complications. The simple model structure did not
result in divergent results compared to other studies in
Queiroga et al. [31], but Fairbairn et al. [24] found that
TAVI is dominant while all other studies comparing TAVI
with SAVR found high ICERs or that TAVI was dominated
by SAVR.
Only one study described who was involved in devel-
oping the model structure [33]. Two studies reported
information about developing the model structure [22, 32],
but they did not explicitly discuss this process nor referred
to an underlying conceptual model. Cooper et al. also
found that few studies (10%) report the development pro-
cess of the model structure [34]. Transparency of model
development is important to assess to what extent model
development is based on clinical considerations and/or
considerations regarding data availability of model
parameters [10].
Structural assumptions
Several structural assumptions were not reasonable and
some might have impacted the cost-effectiveness results.
For instance, four studies assumed that valve prosthesis
functionality and/or complication rates were similar for
TAVI and SAVR [25, 26, 33] or assumed TAVI valves
retain functionality during the patient’s lifetime [24]. These
assumptions might over- or underestimate the effects of
TAVI, because several studies found significant differences
in post-procedure complications between TAVI and SAVR
[3, 35]; and since TAVI is a relatively new procedure the
long-term effects are unclear.
Further, Orlando et al. [30] assumed that TAVI and ST
patients in the state ‘survival with C 1 episode of hospi-
talisation after initial treatment’ have the same costs and
QALY outcomes, regardless of how many further hospital
admissions occur. If the frequency of further admissions
and reasons for admissions (and thus costs and quality of
life) are different between TAVI and ST patients, this
assumption leads to bias in cost-effectiveness outcomes
which might explain the relatively low ICER reported in
this study [30].
Strategies and comparators
Many studies evaluated TAVI, but the implantation routes
differed. Most studies investigated transfemoral TAVI
(through the leg), while others investigated transapical
TAVI (through the chest cavity), or combinations of
implantation routes. Further, almost all studies investigated
balloon-expandable transcatheter valve prostheses, while
one study [22] evaluated self-expanding transcatheter valve
S. A. Huygens et al.
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prostheses. There was no clear trend in cost-effectiveness
outcomes of studies considering different implantation
routes or types of prostheses. However, two studies using
comparable methods to determine the cost-effectiveness of
both implantation routes reported a more favourable ICER
for transfemoral than transapical TAVI compared to ST
and SAVR [25, 26]. This might be explained by higher
disease severity of patients undergoing transapical TAVI;
which are often patients with a porcelain aorta who are not
eligible for transfemoral TAVI.
The definition of ‘standard treatment (ST)’ or ‘medical
management (MM)’ differed between studies. In studies
based on the PARTNER trial [22, 23, 27–29, 31–33] ST
includes MM and is combined with balloon aortic valvu-
loplasty (BAV) in more than 80% of patients. In other
studies the comparator is MM without BAV. The ICERs of
studies considering sole MM are not clearly different from
studies considering ST as comparator. However, Simons
et al. [32] performed separate analyses for TAVI compared
to ST with and without BAV and found a more favourable
ICER for TAVI compared to ST without BAV than with
BAV [32].
Time horizon
The appropriate time horizon when evaluating the cost-
effectiveness of heart valve implantations is lifetime,
because the interventions affect mortality rates [36].
Although the time horizons of the studies might seem
different, time horizons of 10 years or longer are equiva-
lent to lifetime because of the high age of patients under-
going valve replacement (±80 years). In four studies the
time horizon is too short (1–5 years) to capture all relevant
differences between interventions [22, 27, 29, 31]. There
was no clear association between time horizon and cost-
effectiveness outcomes, except for the study of Neyt et al.
who reported a high ICER of TAVI compared to SAVR,
that might be explained by the short time horizon (1 year)
during which the high procedure costs cannot be com-
pensated with potential increased life expectancy [29].
Cycle length
Common practice after heart valve implantations is to
schedule follow-up visits at least once a year [37]. There-
fore, the appropriate cycle length should be 1 year or
shorter. This was the case in all studies, except for one
study that used a cycle length of 5 years [21].
Data identification
Several studies failed to describe their data sources in such
detail that replication of the study using the same data
would be possible [21, 25, 26]. Especially methods of
deriving expert opinion and choices of data sources were
unclear.
Data modelling: baseline data
Since TAVI is a relatively new treatment, (real-world)
clinical effectiveness data are limited. Therefore, many
studies used the PARTNER trial as source for clinical data.
This trial consists of two cohorts: PARTNER-A comparing
TAVI with SAVR in high-risk operable patients [3] and
PARTNER-B comparing TAVI with ST in inoperable
patients [4]. Even though many studies used clinical data
from these cohorts, there are considerable differences in
resulting cost-effectiveness outcomes. Possible explana-
tions for these differences are inclusion of other cost
components or sources, other methods of extrapolation of
survival or utilities beyond the follow-up time of the trial,
variations in time horizon, different model structures,
included complications, etc. [25, 26, 38, 39]. The baseline
characteristics of populations differed between studies,
especially operable risk. Most studies comparing TAVI
with ST included inoperable patients based on the PART-
NER-B trial definition [23, 27–33], while patients in other
studies were at lower operable risk [2, 22, 25, 26]. The
latter studies had lower mean patient ages and fewer
patients in NYHA class III/IV, but they did not report
better cost-effectiveness outcomes [2, 22, 25, 26].
Three studies comparing TAVI with SAVR included
high-risk operable patients based on the PARTNER-A trial
definition [23, 24, 29]. Other studies used slightly different
definitions, resulting in the inclusion of patients with lower
mean age, logistic EuroSCORE and/or proportion of
patients in NYHA class III/IV [2, 25, 26, 30]. Most of these
studies found that TAVI costs more, but gains more
QALYs, while studies using the PARTNER-A trial defi-
nition found that TAVI is dominated by SAVR.
Besides differences between studies, there were differ-
ences in baseline characteristics between groups within
studies that might have influenced the cost-effectiveness
outcomes [22, 30]. For example, Orlando et al. [30] derived
survival estimates from different sources with lower
operable risks for SAVR patients compared to TAVI.
Therefore, SAVR patients survival may be overestimated,
resulting in lower incremental QALY gains due to TAVI.
Further, Neyt et al. [29] based costs of SAVR on patients
with a lower surgical risk (i.e.[70 years with high severity
of illness index, but not selected on operable risk) than the
TAVI patients. This might explain the high incremental
costs of TAVI in this study. In addition, there are unmea-
sured patient characteristics that are not considered in
operable risk scores, such as patient frailty, that are
important in treatment selection [40]. Consequently, this
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might have resulted in other unobservable differences in
patient characteristics between SAVR and TAVI patients
that may have influenced the results.
Data modelling: treatment effects
The time horizon of most models included in this review is
(equivalent to) lifetime, while the follow-up of the clinical
trials that are used as input for mortality and complication
rates is limited to a few years. Therefore, the included studies
needed to make assumptions about survival beyond the trial
data, or needed to extrapolate the available data using sur-
vival analysis techniques. The extrapolation technique of
survival data was reported in most studies (except for
Beresniak et al. [21] and Gada et al. [25, 26]), but there was a
lack of consistency in techniques between studies which
might have influenced cost-effectiveness outcomes.
Three studies explicitly stated using separate parametric
models to fit survival curves for TAVI versus ST because the
proportional hazard assumption did not hold [22, 30, 33].
Brecker et al. [22] and Orlando et al. [30] used a Weibull
distribution, but it was not reported which parametric func-
tion Watt et al. [33] used. The all-cause mortality increases
faster over time in ST than TAVI patients [22], which might
explain the relatively high incrementalQALYgains of TAVI
in these studies [22, 30, 33].
Queiroga et al. [31] also fitted a Weibull distribution to
the observed values, but it is unclear whether separate
functions were fitted for both treatment groups. Further,
Simons et al. [32] used a piecewise exponential curve
accounting for higher mortality rates in ST during the first
6 months than the period thereafter, while other studies
continued the trend of higher mortality beyond 6 months.
This would result in a higher QALY gain after ST in
Simons et al. compared to other studies, which was true for
five of the other seven studies that reported LY (life years)
or QALY gain after ST [22, 27, 28, 30, 33].
Other studies seem to have assumed that the propor-
tional hazard assumption was true from the time of the
intervention until death. Fairbairn et al. [24] assumed the
same constant proportional changes observed from year 1
to year 2 for the years beyond two years after the inter-
vention. Hancock-Howard et al. [27] extrapolated the 1-,
6-, 12- and 24-month survival data from the PARTNER
trial to 36 months using an exponential trend line function.
Neyt et al. [29] assumed that the difference between life
expectancy of TAVI and MM patients remained constant
during the lifetime horizon of the model and after 1 year
the monthly mortality rate increased according to age- and
sex- adjusted mortality rates of the general population. As
expected, these studies reported smaller incremental
QALY differences compared to studies using separate
parametric models for different treatments [22, 30, 33].
Doble et al. [23] based the mortality rates from 2 to
20 years after the intervention on Canadian life tables. This
means that they assume that the intervention has no con-
tinuing effect beyond 2 years after the intervention. This
might explain the small difference in life years after SAVR
and TAVI found in this study (0.01 LY).
Two studies modelled the mortality rate by multiplying
the age- and sex-adjusted mortality rates of the general
population with 1.5 to represent higher than average mor-
tality risk in TAVI patients, whereas the life expectancy of
MM patients was assumed to be 3 years [2, 28]. This
means that the mortality rate in TAVI patients was 50%
higher than the average population, which might explain
the low incremental QALY gain reported in (the high-risk
subgroup of) these studies.
Data modelling: costs
Most studies discounted costs and effects according to
national economic evaluation guidelines, but there were
four studies that did not report whether and how costs and
effects were discounted [21, 25, 26, 28]. Discount rates did
not seem to influence cost-effectiveness outcomes much,
suggesting other differences between studies had a larger
impact on results.
There has been much debate on including costs unre-
lated to the disease or intervention of interest during life
years gained [41]. Simons et al. [32] were the only study
that included additional healthcare costs unrelated to aortic
stenosis or its treatment and management. Since the hazard
rate of death is higher in patients in NYHA class I/II that
received MM with BAV compared to TAVI [32], these
additional healthcare costs are mostly accrued by TAVI
patients. This might explain the relative high ICER found
in this study. This finding is in line with another study that
illustrated that including unrelated medical costs would
increase the ICER of TAVI versus ST [41].
Data modelling: quality of life weights (utilities)
The way to translate PARTNER trial data to utilities dif-
fered between studies resulting in different utility esti-
mates. Seven studies [2, 22–24, 28, 30, 33] calculated
utilities based on utilities per NYHA class derived from
other literature [42–45] multiplied with the proportion of
patients in each NYHA class in the PARTNER trial. The
NYHA class consists of four classes reflecting the patient’s
limitations during physical activity. In contrast with gen-
eral quality of life instruments, the NYHA class is assessed
by clinicians instead of patients and does not consider
social and mental/emotional aspects of quality of life [46].
In addition, applying utilities by NYHA class might
underestimate the uncertainty in utility estimates because a
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change in NYHA class is associated with a fixed change in
utility similar for each patient. This might explain the
relatively high incremental QALY gains due to TAVI in
two studies [22, 33] that used relatively high fixed utility
gains for each lower NYHA class, because 1 year after the
intervention a larger proportion of TAVI patients compared
to ST patients was in a lower NYHA class [4]. Further-
more, utility estimates varied substantially between sour-
ces; not only in absolute value for the same NYHA class,
but also in the differences between NYHA classes [47].
Therefore, indirect utility assessment using NYHA class is
inappropriate and direct utility assessment using prefer-
ence-based quality of life instruments is preferred. How-
ever, we found no clear difference in utility estimates based
on NYHA classes or EQ-5D measurements.
There were several other assumptions about utilities that
might have influenced cost-effectiveness outcomes of the
studies. For example, Orlando et al. [30] made a distinction
between utilities of TAVI survivors with and without
rehospitalisation, that was not applied to MM patients.
Therefore, TAVI patients without rehospitalisation could
gain more QALYs than MM patients without rehospitali-
sation. This might explain the relatively high incremental
QALY gain due to TAVI found in this study.
Assessment of uncertainty
The quality of a decision-analytic model does not only
depend on the methods of determining the point estimate of
the ICER, but also on how uncertainty surrounding this
outcome is considered [48]. Parameter and structure uncer-
tainty were most often addressed, but most studies could be
improved by also considering methodological uncertainty
and heterogeneity. Only six studies reported information on
statistical significance (p values or confidence intervals) of
differences in costs and utilities [21, 22, 25, 29, 32, 33]. In all
but one study [25] the differences were statistically signifi-
cant. Twelve studies reported the probability of being cost-
effective [2, 22–30, 32, 33] and nine studies supported these
probabilities by publishing cost-effectiveness acceptability
curves [2, 23, 24, 27–30, 32, 33].
Consistency (i.e. validity)
The studies did not pay much attention to consistency of
their models. Only three studies [2, 23, 32] reported testing
the mathematical logic of their model (internal consistency,
e.g. model replication with other software) and two studies
calibrated their model against independent data (external
consistency) [29, 32]. Further, about half of the studies did
not compare their results with previous decision-analytic
models [2, 21, 25, 26, 28, 31, 33]. However, when studies
were published before 2012 we assumed that it was not
possible to compare with previous studies because they did
not exist or were published during the time of the study
[2, 21, 25, 26].
Opportunities for future economic models
This review revealed several opportunities for future eco-
nomic models regarding heart valve implantations.
Firstly, gaps in the literature on model based economic
evaluations of heart valve implantations can be filled by
evaluating cost-effectiveness of heart valve implantations
in valve positions other than the aortic valve and by
comparing the cost-effectiveness of SAVR with mechani-
cal or biological valves. Both valve types have their own
strengths and limitations and there are differences in
healthcare use which might influence cost-effectiveness.
Further, it would be interesting to investigate how includ-
ing costs outside of healthcare (societal perspective), such
as productivity and informal care costs, would influence the
cost-effectiveness of heart valve implantations.
Secondly, there are methodological alternatives to the
frequently used decision trees and Markov models, such as
patient-simulation models. Advantages of patient-simula-
tion models are their ability to incorporate recurrent events
and to ‘remember patient history’ without producing
unmanageable numbers of health states, resulting in greater
flexibility in examining the impact of patient characteristics
on outcomes [36, 49].
Thirdly, improvements can be made in the method-
ological quality of studies by describing and justifying
chosen methods and data sources in more detail, per-
forming sensitivity analysis on extrapolation of results,
performing subgroup analyses, and considering method-
ological and structural uncertainty and consistency (i.e.
validity) of the model.
Finally, in this review only two studies used real-world
data from patient registries instead of clinical trials
[21, 22]. In the future, we expect more model-based cost-
effectiveness studies using data from patient registries
including TAVI patients. However, the comparison of
TAVI and ST in these registries will become increasingly
difficult because of the positive results of TAVI in inop-
erable patients of the PARTNER-B trial, which make it
unethical to deny TAVI in these patients. This will lead to
serious selection bias in registry data. In that case, using a
historical cohort of ST patients, for example as in Freeman
et al. [35], might better reflect real-world outcomes in ST.
Limitations
This study has several limitations. Firstly, we experienced
difficulties in using the Philips checklist to assess the
methodological quality of the studies. Some criteria are
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umbrella-criteria that should be assessed differently for
different types of data (i.e. utilities, costs, etc). For many
criteria the methods were described but not explained or
justified. In these cases we decided that the study fulfilled
the criteria but we added a remark that there was no jus-
tification reported. Sometimes criteria were partially ful-
filled which made it difficult to decide if the criteria should
be assessed as fulfilled or not. Therefore, we did not
exclude studies with low scores on the Philips checklist.
Secondly, it was often difficult to fully understand the
details of a decision-analytic model because of space limits
on papers.
Conclusion
This review provided an overview of the existing decision-
analytic models regarding the cost-effectiveness of heart
valve implantations. Our results showed that in most
studies TAVI was cost-effective compared to ST in inop-
erable and high-risk operable patients and in all studies
SAVR was cost-effective compared to ST in operable
patients, but the results were not consistent on the cost-
effectiveness of TAVI versus SAVR in high-risk operable
patients. This review showed that future models can
improve their methodological quality and that there is room
for patient-simulation models considering the cost-effec-
tiveness of heart valve implantations in other valve posi-
tions besides the aortic valve, performed from a societal
perspective.
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